Description:
RETT SYNDROME, CONGENITAL VARIANT
FORKHEAD BOX G1; FOXG1
|
Repository
|
NIGMS Human Genetic Cell Repository
|
| Subcollection |
Heritable Diseases
PIGI Consented Sample
FOXG1 |
|
Cell Type
|
Fibroblast
|
|
Tissue Type
|
Skin
|
|
Transformant
|
Untransformed
|
|
Race
|
White
|
|
Ethnicity
|
Not Hispanic/Latino
|
|
Ethnicity
|
Italian, Eastern European
|
|
Country of Origin
|
BRAZIL
|
|
Family Member
|
1
|
|
Family History
|
N
|
|
Relation to Proband
|
proband
|
|
Confirmation
|
Molecular characterization before cell line submission to CCR
|
|
Species
|
Homo sapiens
|
|
Common Name
|
Human
|
|
Remarks
|
|
| PDL at Freeze |
11 |
| Passage Frozen |
3 |
| |
| IDENTIFICATION OF SPECIES OF ORIGIN |
Species of Origin Confirmed by LINE assay |
| |
| Remarks |
Clinically affected; age at diagnosis 15 months; age of symptom onset 3 months; microcephaly; developmental delay; autistic symptoms; epilepsy; a submitted report summarized details of a translocation: t(2;14); the chr 14 breakpoint is located within the FOXG1 regulatory domain; this 14q12 breakpoint truncates the 3'UTR of the non-coding gene c14orf23 20-24 kb 3' to FOXG1 in a region associated with long-range position effect (LRPE) of FOXG1 with symptoms similar to those of point mutations within FOXG1; the chr 2 breakpoint is within 2q36.1, truncating the gene WDFY1 (expressed at low levels in tissue, not highly expressed in brain); EKG results were normal; EEG results were abnormal and showed signs of focal epilepsy; speech language therapy; physical therapy; occupational therapy; medications include keppra, clobazam, trihexyphenidyl, and melatonin; LCL is GM27260; mother is GM27262 (LCL) and father is GM27264 (LCL)/GM27265 (fibro). |
| Cumulative PDL at Freeze |
11 |
| Passage Frozen |
3 |
| Split Ratio |
1:3 |
| Temperature |
37 C |
| Percent CO2 |
5% |
| Percent O2 |
AMBIENT |
| Medium |
Eagle's Minimum Essential Medium with Earle's salts and non-essential amino acids with 2mM L-glutamine or equivalent |
| Serum |
15% fetal bovine serum Not inactivated |
| Supplement |
- |
|
|